Associate Professor of Medicine
Specialty Areas: Clinical hypertension and nephrology; Clinical drug development
Chronology: B.A. University of North Carolina, Chapel Hill, 1969;M.D. Medical College of Virginia, Va. Commonwealth University, 1973;Medicine Internship: Bowman Gray School of Medicine, 1973-74;Medicine Residency: Medical College of Virginia, 1974-76;Nephrology Fellowship: Duke University Medical Center, 1976-79;Associate in Medicine and Clinical Pharmacology, Duke Medical Center, 1979-81;Assistant Professor of Medicine, Division of Nephrology, 1981-1983;Clinical Assistant/Associate Professor of Medicine, University of North Carolina, Division of Nephrology and Hypertension, 1983-present;Clinical Research Physician/Director, Burroughs Wellcome Co/ Glaxo Wellcome Inc/GlaxoSmithKline, 1983-2002;Medical Director, Lineberry Research Associates/Constella Group, 2002-2007; Independent Clinical Research Consultant, 2008-2014.
Selected Bibliography:
Colindres, RE. And Grossman, SH. Hypertension Secondary to Renovascular Diseases In Netter’s Internal Medicine, 2nd edition. Edited by Runge, MS. and Greganti, A. Saunders, Philadelphia, PA, 2008 pp170-175.
Colindres, RE and Grossman, SH. Hypertension Secondary to Diseases of the Adrenal Gland In Netter’s Internal Medicine, 2nd edition. Edited by Runge, MS. And Greganti,A. Saunders, Philadelphia, PA, 2008 pp176-185.
Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med. 2004 Jan; 32(1): 21-30.
Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR; On behalf of the Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan; 32(1): 13-20.
Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; On behalf of the Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan; 32(1): 1-12.
Roque F. Mon G. Belardi J. Rodriguez A. Grinfeld L. Long R. Grossman S. Malcolm A. Zon G. Ormont ML. Fischman DL. Shi Y. Zalewski A. Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty. Antisense & Nucleic Acid Drug Development 2001; 11(2): 99-106.
O’Connor CM, Gattis WA, Uretsky BF, Adams, KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM for the FIRST Investigators. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure. Insights from the Flolan International Randomized Survival Trial (FIRST). American Heart Journal 1999; 138(1 Pt 1):78-86.
Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, Crow JC, Shaffer CL, and Thorn MD for the Epoprostenol Multicenter Research Group. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. American Journal of Cardiology 1995; 75:34A-43A.
Dillon, JJ, Grossman, SH, Finn, WF. Effect of oxypurinol on renal reperfusion injury in the rat. Renal Failure 1993; 15(1):37-45.
Miles MV, Balasubramanian R, Pittman AW, Grossman SH, Pappa KA, Smith MF, Wargin WA, Findlay JW, Poust RI, Frosolono MF. Pharmacokinetics of oral and transdermal triprolidine. Journal of Clinical Pharmacology 1990; 30(6): 572-575.
Finn, WF, Dillon, JJ, Grossman, SH. Free-radical scavengers in ischemic and nephrotoxic acute renal failure. Renal Failure 1990; 12:52.
Finn, WF, Hak, LJ, Grossman, SH. Protective Effect of Prostacyclin on Postischemic Acute Renal Failure in the Rat. Kidney International 1987; 32:479-487.
Grossman, SH, Davis, D, Gunnells, JC, and Shand, DG. Plasma Norepinephrine in the Evaluation of Baroreceptor Function in Humans. Hypertension 1982; 4(4):566-571.
Mills, SR, Wertman, DE, Grossman, SH. Renal Cortical Arterio- venous Fistula Complicating Percutaneous Renal Angioplasty. American Journal of Roentgenology 1981; 137:1251-1253.
Grossman, SH and Gunnells, JC. Blood Pressure Response to a Single Daily Dose of a Clonidine-Chlorthalidone Combination. Journal of Clinical Pharmacology 1980; 20(4):193-6.
Grossman, S, Gunnells, J, Berrebi, G, Ledbetter, F, Krishna, N, and Mills, S. Pheochromocytoma with Lateralizing Renal Vein Renin Activity (letter). Archives of Internal Medicine 1980; 140:1677.
Watlington, C, King, R, Baldwin, G, Grossman, S, and Estep, H. Chloride-Transport Stimulatory Factor in Urine of Chronically Sodium-Loaded Man. The Lancet 1977; ii, 169-71.
